Microcap Ledger AEON Biopharma, Inc. $AEON
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Pharmaceutical Preparations
- Headquarters
- Aliso Viejo, CA
- Fiscal year end
- December 31
- Shares outstanding
- 49,882,790 [10-Q 2026-08-12]
What the company doesAI summary of filing
AEON Biopharma is a clinical-stage biopharmaceutical company developing ABP-450, a botulinum toxin complex intended as a biosimilar to Botox® for therapeutic medical indications. The company is advancing ABP-450 through the FDA's 351(k) biosimilar pathway with the goal of obtaining regulatory approval across all approved therapeutic indications for Botox®, including chronic migraine, cervical dystonia, spasticity, and overactive bladder. AEON does not currently generate revenue and has never been profitable; the company has an accumulated deficit of $470.8 million as of December 31, 2025, and expects to have sufficient cash to fund operations into the third quarter of 2026. The company holds exclusive development and commercialization rights for ABP-450 therapeutic indications in the United States, Canada, the European Union, the United Kingdom, and certain other territories, with the U.S. therapeutic botulinum toxin market estimated at approximately $3.3 billion in 2025. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$12.95M | −$6.33M | $3.43M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | — | −$39.22M | −$17.31M | $3.01M | [10-K 2026-03-30] |
| FY ended Dec 2024 | — | $42.01M | −$20.29M | $13.0K | [10-K 2026-03-30] |
- Quarterly cash burn
- −$3.17M
- Cash runway Estimate
- ~3.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 39,970,693 | [10-Q 2024-11-13] |
| 2025-03-21 | 10,532,802 | [10-K/A 2025-06-11] |
| 2025-05-07 | 11,305,367 | [10-Q/A 2025-06-11] |
| 2025-08-08 | 1,164,378 | [10-Q 2025-08-12] |
| 2025-11-10 | 11,838,447 | [10-Q 2025-11-14] |
| 2026-03-23 | 25,303,058 | [10-K 2026-03-30] |
| 2026-05-11 | 26,307,211 | [10-Q 2026-05-14] |
| 2026-08-06 | 49,882,790 | [10-Q 2026-08-12] |
- Shelf registration
- S-1 filed 2026-07-08; declared effective 2026-07-13 [S-1 2026-07-08]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-04-03. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-04-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-04-03] |
| 2025-04-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-25] |
| 2025-02-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-07] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-19 | Lynch Timothy P | buy | 1,150,000 | $0.21 | [4 2026-08-21] |
| 2026-06-17 | Thunen Shelley B | grant | 222,684 | — | [4 2026-06-22] |
| 2026-06-17 | Palmisano Robert J | grant | 222,684 | — | [4 2026-06-22] |
| 2026-06-17 | Forth Marc | grant | 222,684 | — | [4 2026-06-22] |
| 2026-06-17 | Fischer Jost | grant | 222,684 | — | [4 2026-06-22] |
| 2026-06-17 | Carter Eric G | grant | 222,684 | — | [4 2026-06-22] |
| 2026-04-02 | Bencich John | grant | 754,717 | — | [4 2026-04-03] |
| 2026-03-04 | Oh Chad | grant | 1,316,872 | — | [4 2026-03-11] |
| 2026-02-17 | Oh Chad | grant | 862,500 | — | [4 2026-03-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-30 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-21 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-03 | 8-K | Regulation FD disclosure; Other events |
| 2026-07-23 | 8-K | Other events |
| 2026-07-21 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-15 | 8-K | Material agreement entered; Other events |
| 2026-07-15 | 424B4 | Prospectus or prospectus supplement |
| 2026-07-09 | S-1/A | Registration statement |
| 2026-07-08 | S-1 | Registration statement |
| 2026-06-17 | 8-K | Shareholder vote results |
Alerts for $AEON
Email me when AEON Biopharma, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.